Veru share price logo

Veru

NASDAQ: VERU

$2.44

+0.03

(+1.45%)

as on

Veru Stock Performance

as on September 22, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $2.43
    $2.48
    downward going graph

    0.41%

    Downside

    1.64%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $2.05
    $7.33
    downward going graph

    15.98%

    Downside

    200.41%

    Upside

    downward going graph

Veru share price movements today

Previous Close
$2.41
Open
$2.44
Volume
546.6K
Market Cap
$41.1M
Day's Low - High
$2.43 - $2.48
52 Week Low - High
$2.05 - $7.33

Veru Historical Returns

1 Month Return
-8.71 %
3 Month Return
-18.31 %
1 Year Return
-30.55 %
3 Year Return
-74.51 %
5 Year Return
-97.23 %

Veru Stock Fundamentals & Key Indicators

Check Veru market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$41.1M

EPS (TTM)

-0.601

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-4.01

Industry PE ratio

-2.34

PEG Ratio

-0.02420713624803807

EBITDA

-27.0M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-45.89%

Veru Stock Valuation

Track how Veru P/E has moved over time to understand its valuation trends.

Veru in the last 5 years

  • Overview

  • Trends

Lowest (-11.02x)

September 30, 2022

Today (-2.45x)

September 30, 2025

Industry (-2.34x)

September 30, 2025

Highest (87.99x)

September 30, 2021

LowHigh

Today’s Price to Earnings Ratio: -2.45x

Veru vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Veru with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Veru image
Veru
Buy$41.1M-97.23%-4.010.00%0.00%
Moderna image
Moderna
Neutral$61.5B-64.51%-19.3-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$130.1B174.21%29.8186.04%0.00%
Regeneron image
Regeneron
Buy$80.8B21.32%18.4884.86%0.47%

Stock Returns calculator for Veru Stock including INR - Dollar returns

The Veru stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Veru investment value today

Current value as on today

₹76,291

Returns

-₹23,709

(-23.71%)

Returns from Veru Stock

-₹29,683 (-29.68%)

Dollar Impact

₹5,974 (+5.97%)

Analyst Recommendation on Veru Stock

Based on 9 analysts

BUY

88.89%

Buy

11.11%

Hold

0.00%

Sell

Based on 9 analysts, 88.89% of analysts recommend a 'BUY' rating for Veru. Average target price of $24.5

Veru Share Price Target

Get share price movements and forecasts by analysts on Veru.

What analysts predicted

90.04%UPSIDE

Target Price

$24.5

Current Price

$2.44

Analyzed by

9 Analysts

Target

$24.50

Veru target price $24.5, a slight upside of 90.04% compared to current price of $2.44. According to 9 analysts rating.

Indian Investors' Interest in Veru Stock

Search interest for Veru Stock has decreased by -14% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-14% versus previous 30 day period

Veru Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
4
3
6
-
-
-
-
-
-
-
Gross Profit
0
1
2
-
0
-
-
0
0
-
Operating Income
-9
-10
-8
-10
-8
-7
1
-5
-7
-7
EBITDA
-9
-10
-7
-10
-9
-8
-7
-5
-7
-6
Interest Expense
0
0
0
-
-
-
-
-
-
-
Depreciation
-
0
0
0
0
0
0
0
0
-
Income Before Tax
-9
-10
-8
-1
-7
-7
1
-5
-3
-6
Income Tax Expense
0
0
0
-
-
-
-
-
-
-
Net Income
-10
-10
-8
-8
-7
-7
1
-5
-2
-6
Net Profit Margin
16.40%
33.84%
40.37%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Veru Annual Profit & Loss

All numbers in Millions USD

Sep 2017
Sep 2018
Sep 2019
Sep 2020
Sep 2021
Sep 2022
Sep 2023
Sep 2024
Sep 2025
Total Revenue
13
15
31
42
61
39
16
16
-
Gross Profit
7
8
21
30
47
30
7
5
0
Operating Income
-8
-20
-6
-14
12
-83
-93
-36
-24
EBITDA
-8
-19
-7
-14
9
-79
-89
-36
-35
Interest Expense
2
2
4
4
4
4
2
0
-
Depreciation
0
0
0
0
0
0
0
0
0
Income Before Tax
-8
-23
-12
-20
4
-83
-92
-37
-15
Income Tax Expense
-1
0
0
-1
-3
0
0
0
-
Net Income
-6
-23
-12
-18
7
-83
-93
-37
-22
Net Profit Margin
51.40%
55.36%
68.10%
72.28%
78.24%
77.73%
46.43%
34.67%
0.00%

Veru Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-10
-10
-8
-8
-7
-7
1
-5
-2
-6
Operating Cash Flow
-5
-5
-4
-11
-7
-5
-5
-6
-8
-5
Investing Cash Flow
0
0
0
17
1
0
6
-
3
1
Financing Cash Flow
0
0
-
-4
-
-
-
23
-
0
Change in Cash
-5
-5
-4
1
-6
-5
0
17
-5
-3

Veru Annual Cash Flow

All numbers in Millions USD

Sep 2017
Sep 2018
Sep 2019
Sep 2020
Sep 2021
Sep 2022
Sep 2023
Sep 2024
Sep 2025
Net Income
-6
-23
-12
-18
7
-83
-93
-37
-22
Operating Cash Flow
0
-11
-5
-1
-15
-47
-88
-21
-30
Investing Cash Flow
0
0
0
0
14
4
6
0
25
Financing Cash Flow
-
12
8
9
109
1
11
36
-4
Change in Cash
0
0
2
7
108
-42
-70
15
-9

Mutual Funds that own Veru Stock

Check out the Mutual Funds with significant holdings in Veru.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
3.163471%
539382
Fidelity Concord Street Trust
0.752443%
128294
MORGAN STANLEY PATHWAY FUNDS
0.047682%
8130
Victory Portfolios III
0.042398%
7229
SCHWAB CAPITAL TRUST
0.038122%
6500
See all

Global Institutional Holdings in Veru

Funds
Holdings
Vanguard
4.05%
iShares
0.29%

Veru News & Key Events

  • img

    Today's Timeline - 08 September

    Tue, 06:17 PM

    -

    Veru refocuses sabizabulin on oncology, advancing to Phase 2 trial for KRAS-driven metastatic pancreatic cancer.

Insights on Veru

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, VERU stock has moved up by 3.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 510.3% return, outperforming this stock by 540.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 53.7% return, outperforming this stock by 128.2%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 6.65M → 56.38K (in $), with an average decrease of 86.7% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -2.74M → -6.98M (in $), with an average decrease of 154.9% per quarter

About Veru

Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
OrganisationVeru
Headquarters2916 North Miami Avenue, Miami, FL, 33127, US
IndustryBiotechnology
CEOMitchell S. Steiner
E-voting on sharesClick here to vote

Key Management of Veru

Name

Title

Ms. Michele Greco CPA

CFO & Chief Administrative Officer

Mr. Martin Tayler

Executive Vice President of FC2 Global Operations

Dr. Gary Bird Ph.D.

Executive Vice President of Quality & Regulatory Affairs

Dr. K. Gary Barnette Ph.D.

Chief Scientific Officer

Dr. Harry D. Fisch F.A.C.S., M.D.

Vice Chairman & Chief Corporate Officer

Mr. Samuel Fisch

Executive Director of Investor Relations & Corporate Communications

Mr. Philip R. Greenberg J.D.

Executive VP, General Counsel & Secretary

Mr. Kevin J. Gilbert CPA, J.D.

Executive Vice President of Corporate Development

Dr. Domingo Rodriguez M.D.

Executive Vice President of Global Clinical Operations

Dr. Mitchell S. Steiner F.A.C.S., M.D.

Chairman, President & CEO

FAQs

What is Veru share price today?

Veru share price today is $2.44 as on at the close of the market. Veru share today touched a day high of $2.48 and a low of $2.43.

What is the 52 week high and 52 week low for Veru share?

Veru share touched a 52 week high of $7.33 on and a 52 week low of $2.05 on . Veru stock price today i.e. is closed at $2.44,which is 66.71% down from its 52 week high and 19.02% up from its 52 week low.

What is Veru's market capitalisation today?

Veru market capitalisation is $0.00T as on .

How to invest in Veru Stock (VERU) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Veru on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Veru Shares that will get you 0.6148 shares as per Veru share price of $2.44 per share as on September 22, 2026 at 1:29 am IST.

What is the minimum amount required to buy Veru Stock (VERU) from India?

Indian investors can start investing in Veru (VERU) shares with as little as ₹95.805 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹958.05 in Veru stock (as per the Rupee-Dollar exchange rate as on ). Based on Veru share’s latest price of $2.44 as on September 22, 2026 at 1:29 am IST, you will get 4.0984 shares of Veru. Learn more about fractional shares .

What are the returns that Veru has given to Indian investors in the last 5 years?

Veru stock has given -97.23% share price returns and 30.09% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?